IONIS PHARMACEUTICALS INCIONIS PHARMACEUTICALS INCIONIS PHARMACEUTICALS INC

IONIS PHARMACEUTICALS INC

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−0.96EUR
Revenue estimate
‪121.80 M‬EUR
Market capitalization
‪5.68 B‬EUR
−2.318EUR
‪−331.86 M‬EUR
‪713.62 M‬EUR
‪133.94 M‬
Beta (1Y)
1.00

About Ionis Pharmaceuticals, Inc.

CEO
Brett P. Monia
Headquarters
Carlsbad
Employees (FY)
927
Founded
1989
FIGI
BBG006TLR1F0
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on TRADEGATE exchange IONIS PHARMACEUTICALS INC stocks are traded under the ticker ISI.
IONIS PHARMACEUTICALS INC is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
ISI earnings for the last quarter are −0.97 EUR per share, whereas the estimation was −0.95 EUR resulting in a −2.15% surprise. The estimated earnings for the next quarter are −0.73 EUR per share. See more details about IONIS PHARMACEUTICALS INC earnings.
IONIS PHARMACEUTICALS INC revenue for the last quarter amounts to ‪136.22 M‬ EUR despite the estimated figure of ‪129.47 M‬ EUR. In the next quarter revenue is expected to reach ‪157.76 M‬ EUR.
Yes, you can track IONIS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
ISI net income for the last quarter is ‪−8.15 M‬ EUR, while the quarter before that showed ‪−139.45 M‬ EUR of net income which accounts for 94.15% change. Track more IONIS PHARMACEUTICALS INC financial stats to get the full picture.
No, ISI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ISI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IONIS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
ISI reached its all-time high on Apr 8, 2019 with the price of 76.610 EUR, and its all-time low was 17.780 EUR and was reached on May 27, 2016. View more price dynamics on ISI chart.
See other stocks reaching their highest and lowest prices.
As of May 6, 2024, the company has 927.00 employees. See our rating of the largest employees — is IONIS PHARMACEUTICALS INC on this list?
We've gathered analysts' opinions on IONIS PHARMACEUTICALS INC future price: according to them, ISI price has a max estimate of 78.99 EUR and a min estimate of 26.95 EUR. Watch ISI chart and read a more detailed IONIS PHARMACEUTICALS INC stock forecast: see what analysts think of IONIS PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IONIS PHARMACEUTICALS INC EBITDA is ‪−299.99 M‬ EUR, and current EBITDA margin is −42.05%. See more stats in IONIS PHARMACEUTICALS INC financial statements.